Core Viewpoint - Phathom Pharmaceuticals has appointed Sanjeev Narula as Chief Financial and Business Officer to enhance its leadership team and support its growth strategy, particularly in achieving profitability and increasing shareholder value [1][2][7]. Company Overview - Phathom Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, specifically through its product VOQUEZNA, a potassium-competitive acid blocker [5]. Leadership Appointment - Sanjeev Narula brings extensive experience from his previous roles, including Chief Financial Officer at Intra-Cellular Therapies, where he played a significant role in its $14.6 billion acquisition by Johnson & Johnson [3]. - Narula has held senior finance positions at Pfizer, Viatris, and Upjohn, contributing to his expertise in capital strategy, M&A, and financial planning [4]. Product Information - VOQUEZNA is marketed in the U.S. for various gastrointestinal conditions, including heartburn associated with Non-Erosive GERD and as part of treatment for H. pylori infection [5].

Core Insights - Phathom Pharmaceuticals, Inc. clarified that a Schedule 13D filing by Frazier Life Sciences will include administrative changes to its reporting approach without indicating a reduction in ownership position by any Frazier fund or individual in Phathom [1] - The differences in the breakout of holdings between funds and individuals are attributed solely to clarifying changes in Frazier's reporting approach, not due to any sale of shares [2] Company Overview - Phathom Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases [3] - The company has in-licensed exclusive rights to vonoprazan, a first-in-class potassium-competitive acid blocker (PCAB), which is marketed in the U.S. under the brand VOQUEZNA® for various gastrointestinal conditions [3]

Core Insights - Phathom Pharmaceuticals reported significant revenue growth in Q2 2025, with net revenues of $39.5 million, up from $7.3 million in Q2 2024, driven by the commercial success of VOQUEZNA products [5][6][11] - The company aims to achieve profitability by 2026, supported by a refined commercial strategy focusing on high-value prescribers and strong prescription trends [2][6][11] Business Highlights - Over 580,000 VOQUEZNA prescriptions have been filled to date, reflecting a 49% increase since the last earnings report [6][7] - Approximately 173,000 VOQUEZNA prescriptions were filled in Q2 2025, representing a 36% sequential growth from Q1 2025 [7] - The prescriber base has expanded, with over 29,300 unique healthcare providers writing prescriptions, a 24% increase since the last quarterly update [7] Financial Performance - R&D expenses for Q2 2025 were $9.1 million, an increase from $7.4 million in Q2 2024, primarily due to one-time restructuring charges [11] - SG&A expenses rose to $85.3 million in Q2 2025 from $75.9 million in Q2 2024, driven by higher personnel-related costs [11] - The net loss for Q2 2025 was $75.8 million, compared to $91.4 million in Q2 2024, with a non-GAAP adjusted net loss of $56.5 million [11][19] Market Position and Strategy - The FDA granted 10-year New Chemical Entity exclusivity for VOQUEZNA, extending market protection until May 2032, which is expected to delay generic competition until at least 2033 [7] - The company has shifted its sales strategy to prioritize gastroenterologists over primary care physicians to enhance prescriber engagement [7] Future Outlook - Phathom expects full-year 2025 revenue to be between $165 million and $175 million, based on strong prescription trends and a refined commercial strategy [6][11] - The company anticipates non-GAAP operating expenses to decrease to less than $60 million in Q3 2025 and less than $55 million in Q4 2025 [11]

Core Viewpoint - Phathom Pharmaceuticals, Inc. will host a live webcast on August 7, 2025, to report its second quarter 2025 financial results and provide a business update [1]. Company Overview - Phathom Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases [3]. - The company has in-licensed exclusive rights to vonoprazan, a first-in-class potassium-competitive acid blocker (PCAB) [3]. - Vonoprazan is marketed in the U.S. as VOQUEZNA for various gastrointestinal conditions, including heartburn relief associated with Non-Erosive GERD and treatment of H. pylori infection [3].

Core Insights - Phathom Pharmaceuticals has appointed Anne Marie Cook as Chief Legal Officer and Corporate Secretary, bringing extensive legal expertise in the pharmaceutical industry [1][2][3] Company Overview - Phathom Pharmaceuticals focuses on developing and commercializing novel treatments for gastrointestinal diseases [6] - The company has in-licensed exclusive rights to vonoprazan, a first-in-class potassium-competitive acid blocker (PCAB), marketed in the U.S. as VOQUEZNA for various gastrointestinal conditions [6] Leadership Background - Anne Marie Cook has a strong background in pharmaceutical law, having served as Senior Vice President and General Counsel at Sage Therapeutics, and held legal leadership roles at Aegerion, ViaCell, and Biogen [2][4] - Cook's experience includes overseeing legal activities related to commercialization, regulatory compliance, intellectual property, and corporate governance [4] Strategic Vision - The CEO of Phathom, Steven Basta, expressed confidence that Cook's skills will significantly impact the company's growth and corporate strategy [3] - Cook emphasized her commitment to helping Phathom redefine the standard of care in acid-related gastrointestinal diseases and create value for stakeholders [3][4]

Core Insights - Phathom Pharmaceuticals has partnered with Kenan Thompson to raise awareness about gastroesophageal reflux disease (GERD) through the "GERD IS NO JOKE" campaign, highlighting the importance of discussing treatment options with healthcare providers [1][7][10] Company Overview - Phathom Pharmaceuticals is focused on developing and commercializing innovative treatments for gastrointestinal diseases, specifically through its product VOQUEZNA (vonoprazan), which is the first FDA-approved potassium-competitive acid blocker (PCAB) for GERD management [23][20] - VOQUEZNA is approved for adults for the relief of heartburn associated with Non-Erosive GERD and for the treatment of Erosive Esophagitis, addressing a significant unmet need in the GERD patient population [20][18] Industry Context - Over 65 million people in the U.S. suffer from GERD, with approximately 70% having Non-Erosive GERD and 30% having Erosive GERD, indicating a large market potential for effective treatments [3][18] - The campaign aims to empower individuals with GERD to engage in open discussions with their healthcare providers about treatment options, particularly VOQUEZNA, which offers rapid and durable acid suppression compared to traditional medications [6][7]